China NMPA Approves NUZYRA® as a Category 1 Innovative Drug

NUZYRA demonstrated efficacy against common pathogens in three Phase 3 studies, including pathogens resistant to other antibiotic classes as a potential...

Related Keywords

Shanghai ,China ,Taiwan ,United States ,Hong Kong ,Jing Zhang ,Henan ,Cambridge ,Cambridgeshire ,United Kingdom ,Macau ,Chinese ,Harald Reinhart ,Haihui Huang ,Zai Lab ,Drug Administration ,Paratek Pharmaceuticals Inc ,Zai Lab Limited ,Drug Clinical Trial Center ,Exchange Commission ,China National Medical Products Administration ,Research Institute ,Fudan University Affiliated Huashan Hospital ,Infectious Diseases At Zai Lab ,Zai Lab Forward ,Lab Limited ,New Drug Application ,Chief Medical Officer ,Infectious Diseases ,Professor Haihui Huang ,Chief Physician ,Deputy Director ,Antibiotic Research ,Professor Jing Zhang ,Drug Clinical Trial ,Paratek Pharmaceuticals ,Greater China ,Private Securities Litigation Reform Act ,Nasdaq Zlab ,